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Introduction
Uncoupling protein 4 (UCP4) belongs to the large family of mitochondrial anion carriers. Although it was first described in 1999 [1] , its function and distribution at protein level are still unknown. Like UCP1, which is a key player in non-shivering thermogenesis mediated by brown adipose tissue (BAT) [2, 3] , UCP4 is thought to regulate proton leak [1, 4, 5] because of its homology to UCP1 (approx. 30%) and the reduction of mitochondrial membrane potential after UCP4 ectopic non-neuronal expression [1, 6, 7] . However, its ability to transport protons has not been directly demonstrated. Even if UCP4-mediated proton transport is confirmed, this would not necessarily imply a definite physiological role, as is the case for several members of the mitochondrial anion carrier family (e.g. ANT [8] , oxoglutarate carrier [9] ), which can perform as proton transporters when expressed in artificial systems. Although phylogenetic analysis shows that UCP4 and UCP5 are more closely related to oxoglutarate and dicarboxylate carriers than to UCP1/UCP2/UCP3 [10] , the existence of unique uncoupling protein signature sequences, which is lacking e.g. in the oxoglutarate carrier [11] , may justify their assignment to a distinct cluster of the mitochondrial anion carrier family, the UCP subfamily.
mRNA of UCP4 and two other uncoupling proteins, UCP2 and UCP5 (BMCP1), has been found in the nervous system (NS) [12, 13] . The presence of three proteins with identical function in the NS would be surprising. In fact, (i) the functions and/or (ii) the localization/ expression levels within the NS may differ between these UCPs. (i) Function in NS has not yet been clearly determined for any UCP. Based on their putative proton transport activity, NS-related UCPs were originally proposed to participate in thermogenesis, e.g. by modulating pre-and post-synaptic events by axonal thermogenesis [7, 14] . However, no reliable evidence has been found apart from the fact that UCP4-mRNA expression is increased in neurons exposed to cold temperatures [6, 7] . Other hypotheses propose that these proteins participate in the regulation of ROS production or calcium homeostasis [15] [16] [17] [18] . Both possibilities are currently debated fiercely [16, [18] [19] [20] . The early occurrence of UCP4 and UCP5 homologs in the simplest multicellular organisms supports the speculation that they might be involved in apoptosis in the mammalian brain [1, [21] [22] [23] . Alternatively, the proton gradient may be used for the translocation of FA peroxides outside of mitochondria [24] .
(ii) The function(s) of UCP4 and other NS-related UCPs will remain elusive until the transport activity of these proteins and protein expression patterns under physiological and pathological conditions are elucidated. The reason for the scarce and controversial data on the UCP2, UCP4 and UCP5 protein distributions may be the lack of reliable specific antibodies (ABs), due to the highly hydrophobic nature of proteins, high sequence homology between members of mitochondrial anion carrier family, and poor accessibility to protein localized on the inner mitochondrial membrane. Most functional studies of UCPs found in NS rely on mRNA determination (for review [4, 25] ). However, UCP2 mRNA found in different organs failed to predict the amount or even the presence of UCP2 protein: whereas UCP2 mRNA was found ubiquitously, UCP2 protein could be only detected in spleen, stomach, lung and white adipose tissue (WAT) [26] . Surprisingly, no UCP2 could be detected in brain and spinal cord under physiological conditions [26] . The distribution of UCP4 mRNA observed by various research groups is controversial. UCP4 mRNA was found in different brain regions including fetal brain [1] , spinal cord [6] , in peripheral nervous system and kidney [27] . UCP5 at mRNA level has been detected in mouse brain, testis, WAT, kidney, brown adipose tissue (BAT), skeletal muscle, liver, and heart [7] . UCP4 and UCP5 have not been yet studied at protein level in detail.
The main goal of the present study was to elucidate the distribution pattern of UCP4 protein under physiological conditions and during development. For this, we designed two antibodies against UCP4 and evaluated these using recombinant proteins, organs, tissue extracts and cell cultures. The results are discussed in terms of UCP4's possible functions.
Materials and methods

Cell cultures
Hippocampal rat neurons
With slight modifications, hippocampal neurons were prepared and cultivated from embryonic days 18-19 (E18-E19) Wistar rats as previously described [28] . Briefly, dissociated cells were plated onto poly-L-lysine-coated glass coverslips at a density of 50-100 cells/ mm 2 . After 3 h in vitro, medium was changed to Neurobasal A medium supplemented with 2% B27 (Gibco®Invitrogen Cell Culture, Karlsruhe, Germany) and the antibiotics penicillin and streptomycin. After 8-21 days in culture, the cells were processed by means of immunofluorescence or Western blotting.
Cortical neuron cultures from embryonic mice
Serum-free preparation of cortical primary cultures was performed with E17 (± 0.5 days) mouse embryos (C57BL/6) [29] . Embryonic cortices were mechanically dissociated in HBSS buffer (without Ca 2+ and Mg
2+
) with trypsin (0.25%) for 10 min at 37°C. Trypsination was stopped by adding minimum essential medium, supplemented with 0.6% glucose, 10% horse serum (Gibco®Invitrogen Cell Culture, Karlsruhe, Germany), and antibiotics penicillin and streptomycin. Further mechanical dissociation was performed by adding additional DNAse I (0.06%). Cells were cultured on poly-Llysine-coated coverslips at a density of 75,000 cells/cm 2 . After 3 h in vitro, medium was changed to Neurobasal A medium supplemented with 2% B27 (Gibco®Invitrogen Cell Culture, Karlsruhe, Germany), 0.5 mM glutamine, and the antibiotics penicillin and streptomycin. After 8-21 days in culture, the cells were processed by means of immunofluorescence or Western blotting.
Astrocyte and microglia cultures from mouse
For astrocyte and microglia preparation, neocortex from mouse pups aged P1-P3 was isolated [30] . The tissue was washed in DMEM 4.5 g/l glucose, containing 10% fetal bovine serum, 200 mM glutamine (Invitrogen) and 100 U/ml penicillin/streptomycin. Following careful homogenization with a fire-polished Pasteur pipette und centrifugation at 300 ×g, 4°C for 1 min the supernatant was transferred into a new tube, homogenized again and centrifuged for 5 min at 1200 ×g, 4°C. The pellet was resuspended in fresh medium and plated in culture flasks, which had been pre-coated with poly-L-lysine. The cells were incubated at 37°C with 5% CO 2 . After two days medium was changed for fresh medium and the cells were allowed to continue incubating until most of the microglia had detached from the astrocytes. To remove the remaining microglia attached to the astrocytes the cells were shaken for 2 h at 37°C. Afterwards the supernatant was plated again in culture medium containing 2% fetal calf serum. The astrocytes still attached to the bottom of the culture flask were used for further experiments.
Production of recombinant uncoupling proteins
Cloning, expression and purification of mouse UCP4-eGFP and mouse UCP5 are described in the Supplementary material. Production of recombinant mouse UCP1 was described previously [31] [32] [33] . Recombinant human UCP2 was donated by Dr. P. Jezek (Prague, Czech Republic). Because the N-terminal peptide sequence of mouse UCP2 has 100% homology to human UCP2, the latter was used in our experiments for the evaluation of mouse UCP4 antibody. The abbreviations UCP1, UCP2, UCP4 and UCP5 are used for both the human and mouse proteins throughout the text.
Animals
Female C57BL/6 mice aged 1 day, 10 days, 30 days and 5 months (12 mice of each age group) were purchased from the animal facility of the Free University Berlin (Germany) and Charles River (Sulzfeld, Germany). Animals were deeply anesthetized with a mixture containing ketamine (Pfizer, Karlsruhe, Germany) and xylazine (Rompun @ , Bayer, HealthCare, Leverkusen, Germany), then transcardially perfused with cold 0.1 M phosphate buffer saline (PBS). Brain, spinal cord, thymus, heart, small intestine, testis, white adipose tissue, skeletal muscles, lung, spleen, stomach, adrenal gland, liver, and kidney were removed, frozen in liquid nitrogen and stored for further Western blot analyses at −80°C. For immunohistochemistry, tissues were collected after perfusion with 4% paraformaldehyde (PFA).
Purification of mitochondria from various mouse tissues
For preparation of pure mitochondria adult female mice (C57BL/ 6J) were sacrificed by atlantoaxial dislocation. Brain, kidney and liver were taken out immediately and immersed in ice-cold phosphate buffered saline (PBS). During subsequent processing the tissues from each single animal were kept separate, no pooling took place. Brain and kidney were first meshed with a pair of scissors. Then, after addition of 1 ml isolation medium [84 ml medium A (0.1 M sucrose, 1 mM EDTA, 20 mM MOPS, pH 7.4 and 1 g/l BSA) + 10 ml 100 mM triethanolamine + 1 ml 100 mM phenylmethylsulfonylfluoride (PMSF) + 5 g Percoll™ + 2 Complete™ tablets (Roche, Mannheim, Germany) + 18.2 mΩ Millipore water to a final volume of 100 ml] the cells were disrupted with 5 up-and down-strokes of a tightly fitting Potter-Elvehjem-homogenizer (Heidolph, Schwabach, Germany) at 1000 rpm. The homogenate was centrifuged at 600 ×g for 10 min, and the supernatant was collected. The liver tissue was disrupted after addition of 2 ml of the isolation medium with an Ultraturax™ Fig. 1 . Design of antibodies to UCP4 and their validation. A. Putative structure of UCP4 based on data for UCP1 [45] and hydrophobicity plot for UCP4. Localization of peptides used for rabbit immunization is marked in red (UCP4-1) and black (UCP4-8). B. Comparison of mitochondrial carriers with the highest homology to UCP4 (Slc25/27) in NCBI BLAST/protein blast. The sequence of N-terminus peptide used for rabbit immunization is marked in red. The alignment of the N-Termini of mitochondrial carriers was performed using the ClustalW program. Signature sequence motif of the SLC25 family [46] is marked in bold. C. Evaluation of the antibody against UCP4 in Western blot. Anti-UCP4 AB detects recombinant UCP4-eGFP (63 kDa), but not recombinant UCP1, UCP2, UCP5. Recombinant UCP1, UCP2, and UCP5 were detected by specific anti-UCP1, anti-UCP2, anti-UCP5 antibodies (AB), respectively. Maximal 1 µg recombinant protein was loaded per lane. D. Co-localization of UCP4 with mitochondria of rat neurons. Culture of rat primary hippocampal neurons was immunostained for UCP4 and visualized by confocal microscopy using Alexa 568 as secondary AB (red). Mitochondria were counterstained with MitoTracker 633 (green). Scale bar, 20 µm.
(Heidolph) and centrifuged at 600 ×g for 10 min after which the supernatant was collected. Subsequently the collected 600 ×g supernatants were centrifuged at 10,000 ×g for 10 min and the pellet was resuspended in washing buffer [0.25 M sucrose, 0.1 mM EDTA].
The crude mitochondrial preparation was loaded onto a continuous gradient consisting of 8 ml of 30% (v/v) Percoll™ in washing buffer and centrifuged continuously at 50,000 ×g for 90 min at 4°C in a Sorvall™ T1270 rotor. After centrifugation two separate rings had formed and the lower ring (the mitochondrial fraction) was aspirated, washed with washing buffer and centrifuged at 10,000 ×g for 10 min. The pellets were stored at − 80°C.
Western blot analysis
Protein samples for Western blots were obtained from mouse tissue, mitochondria and cell cultures. Tissue and mitochondria samples were Fig. 2 . Tissue expression of UCP4. A. Representative Western blot of total lysates from neuronal (1-brain) and non-neuronal (2-spleen, 3-lung, 4-thymus, 5-heart, 6-skeletal muscle, 7-white adipose tissue, 8-testis and 9-adrenal gland) tissues of adult mice using anti-UCP4 AB. Anti-GAPDH AB and anti-VDAC AB were used as control for the sample loading. For each lane 50 µg protein was loaded. B. Representative Western blot of isolated mitochondria lysates from liver (a), kidney (b) and brain (c) using anti-UCP4 AB and anti-VDAC AB as a loading control. 10 µg mitochondrial protein was loaded per lane. C. CLSM of hepatic lobule from adult C57BL/6 mouse liver. Vibratome sections (50 µm thick) were labeled with anti-UCP4 AB (green), anti-VDAC AB (red) and DAPI (blue). CV -central venule, H -hepatocyte, S -sinusoids. Scale bar 10 µm. D. CLSM image of distal (DT) and proximal tubules (PT) from adult C57BL/6 mouse kidney. Vibratome sections (50 µm thick) were labeled with anti-UCP4 AB (visualized by secondary AB Alexa-488, green), anti-VDAC AB (visualized by Alexa-568, red) and DAPI (blue). Scale bar 10 µm. E. CLSM images of peripheral ganglion cells in adult C57BL/6 mouse stomach (intermuscular plexus). Vibratome sections of stomach were double-labeled using anti-UCP4 AB (green), anti-MAP2 AB (red) and DAPI (blue). Scale bar 5 µm.
crushed in lysis buffer (20 mM Tris; 0.25 mM sucrose; 5 mM EDTA; 1 mM EGTA; pH 7.5) with protease inhibitor cocktail (Sigma, Germany). Cultured cells were washed with ice-cold 0.9% NaCl and collected in lysis buffer. After sonication (Bandolin Sonoplus GM70: 3 × 3 s, continuous mode) lysate was incubated for 30 min on ice before centrifugation for 10 min at 2500 rpm. The supernatant was stored at −20°C.
At least 10 µg protein was loaded on 15% SDS-Gel. Precision Plus Protein Dual Color Standard (Bio Rad, Germany) was used as size marker. After gel running, blotting was accomplished with nitrocellulose membrane BA 85 (Schleicher&Schüll, Germany) using a Semi-Dry Electro Blotter (PEQLAB, Germany) for 50 min at 14 V. Blocking was performed for at least 1 h at room temperature (RT) in 1 × TBS-buffer; 2% BSA; 0.05% Tween 20; 0.02% Thimerosal. The membranes were first incubated with affinity purified antibody (AB) against mUCP4 (1:500) overnight at 4°C in the same buffer. After washing 3 times (1× TBS; 0.05% Tween 20) they were incubated with secondary horseradish peroxidase conjugated AB (1:5000, anti-rabbit IgG; GE Healthcare, UK) in block solution for 1 h at RT. After washing, the immunoreaction was visualized using Pierce ECL Western Blotting Substrate on CL-Xposure films. For quantification, VDAC and actin were consecutively detected at the same membrane. After stripping in 100 mM sodium citrate solution (pH 2.2) for 10 min at RT and washing, the procedure of immunodetection was repeated, starting with blocking. Anti-VDAC, anti-GAPDH or anti-β-actin AB (Table S1 , Supplementary materials) were incubated for 1 h at RT in blocking solution. Anti-mouse IgG (GE Healthcare, UK, dilution 1:5000) served as secondary AB. Immunoblots were quantified by densitometry using Image J (http://rsb.info.nih.gov/ij/).
Immunocytochemistry (ICC) and immunohistochemistry (IHC)
Primary neuronal cell cultures, grown on poly-L-lysine-coated coverslips, were fixed with cold 4% PFA for 20 min, washed in 0.1 M PBS, permeabilized with 0.2% Triton X-100 and incubated in 10% fetal calf serum (Biochrom, Berlin, Germany) for 1 h at RT for blocking of non-specific binding. Thereafter, cells were double-labeled with appropriate primary AB (Table S1, Supplementary materials) overnight at 4°C. Negative control sections were incubated in a similar manner, except that the primary AB was replaced with fetal calf serum. For visualization of primary ABs, secondary ABs (Alexa-488-, Alexa-568-, and Alexa-633-conjugated; Table S1 , Supplementary materials) in block solution were applied for 90 min at RT. After rinsing in PBS, the coverslips were gently adhered to the objective glass with ImmuMount (Thermo Electron Corporation, Pittsburg, PA, USA) or mounting medium with DAPI (Table S1 , Supplementary materials).
For IHC, 50 µm thick sections of brain, spinal cord, liver and kidney were cut with a vibratome (Microm HM-650V, Sigmann Elektronik, Germany). To avoid endogenous peroxidase activity (light microscopy) free-floating vibratome sections were first incubated with 0.3% H 2 O 2 (Sigma, Germany), then permeabilized and blocked with 0.5% Triton X-100 and 10% normal goat serum (Vectashield, Vector Laboratories, Burlingame, USA) for 60 min at RT. Subsequently, tissues were labeled overnight at 4°C with one (for light microscopy) or two (for confocal microscopy) appropriate primary ABs (Table S1 , Supplementary materials). Control sections were incubated only in the presence of normal goat serum and Triton X-100. The visualization of antigenantibody complexes was performed by both immunofluorescence and avidin-biotin-peroxidase complex (ABC) labeling. Biotinylated secondary anti-rabbit or anti-mouse IgG ABs were applied for 90 min at RT. Then sections were incubated with ABC complex for 60 min and developed in 3,3′-diaminobenzidine (DAB, Sigma-Aldrich, Germany). After rinsing in PBS, tissues were mounted on slides, dehydrated through a graded series of ethanol, cleared in xylene, and coverslipped with Entellan @ (Merck, Darmstadt, Germany). For visualization of primary ABs using confocal microscopy, secondary ABs (Alexa-488-, Alexa-568-, and Alexa-633-conjugated; Table S1 , Supplementary materials) in block solution were applied for 90 min at RT. After rinsing in PBS, tissue samples were coverslipped with Immu-Mount (Thermo Electron Corporation, Pittsburg, PA, USA) or mounting medium with DAPI (Table S1 , Supplementary materials).
Light and confocal microscopy
Digital images of selected sections were taken using an Olympus BX-51 microscope (Hamburg, Germany). Confocal images were acquired with an upright laser microscope (Leica DM 2500) equipped with a 63× objective (oil-immersion) using sequential scanning with the 405 nm spectral line of a blue diode laser (for DAPI), the 488 nm line of an argon-ion laser, the 543 nm and 633 nm lines from heliumneon lasers (for Alexa-488, Alexa-568 and Alexa-633 respectively). During the processing stage individual image channels were pseudocolored with red, green and blue corresponding (if not otherwise indicated) to each of the fluorophore emission spectral profiles. All images were merged and compiled using Image J. Background correction and adjustment of brightness and contrast were performed in Image J, equivalent settings were used for control images. Threedimensional (3D) reconstitution was performed using the Volocity 4 Program (Improvision Ltd., Coventry, England).
Results
Design and validation of antibodies against mUCP4
Prior to production of specific ABs against mUCP4, two peptide sequences were chosen based on their localization (Fig. 1A) : KLLPLTQ-RWPRTSK (on the N-terminus 8-21, UCP4-1) and MNQPRDKQGR-GLLYKS (in the third matrix loop, 256-271, UCP4-8). These sequences were compared with records in the NCBI protein bank to exclude homology and later AB cross-reactivity with other mitochondrial anion transporters, including UCP2 and UCP5, present in brain. Sequence alignment of SLC25 family members was performed using the ClustalW program (http://align.Genome.jp) and is shown in Fig. 1B for the UCP4-1 peptide, used in our experiments later. Comparison between mouse and rat UCP4 sequences reveals two mismatches for UCP4-1 and 100% identity for UCP4-8 between both species. UCP4 specific ABs were generated in rabbits against both peptides and later affinity purified on a peptide column (Pineda Antibody Service, Berlin, Germany).
The specificity of ABs was examined by Western blot analysis, immunocytochemistry (ICC) and immunohistochemistry (IHC). Western blots were performed using recombinant uncoupling proteins (UCP4-eGFP, UCP1, UCP2 and UCP5, Fig. 1C ), extracts from mouse brain tissue (Fig. S1, Supplementary material) 
and primary neuronal cultures (1D).
Comparison of ABs to both peptides after immunostaining of neurons revealed that amino acids 8-21 (UCP4-1 peptide, Fig. 1D ) were fully accessible, whereas 256-271 (UCP4-8 peptide, data not shown) barely accessible to the ABs in native mUCP4. As demonstrated in Western blot (Fig. 1C) anti-UCP4-1 AB at dilution 1:1000 correctly recognized both the recombinant UCP4-eGFP (predicted MW 63 kDa) and UCP4 in brain tissue extract (approximately MW 36 kDa, Fig. S1 , Supplementary material). Anti-UCP4-8 AB was unspecific (data not shown) and was omitted from further analyses in this study. Recombinant UCP1, UCP2 and UCP5 were undetectable with the new anti-UCP4-1 AB (Fig. 1C, left were stained with anti-UCP4 AB and specific AB for neurons (anti-Tuj-1), astrocytes (anti-GFAP) and microglia (anti-IBA). Anti-β-actin and anti-VDAC ABs were used as a control for sample loading and mitochondrial number respectively. B. Relative UCP4 gene expression in different mice neuronal cells. UCP4 amount was related to the housekeeping gene GAPDH. C. Representative 3D CLSM images from rat primary hippocampal neurons (stained with MAP2, blue), demonstrating the colocalization of UCP4 (anti-UCP4 AB, green) with mitochondria (anti-VDAC AB, red). The staining patterns for UCP4 and VDAC overlap (yellow) mainly in the cell bodies. Notably, UCP4 is not present in all mitochondria in processes (circle). 3D reconstruction of images taken at different z-levels was performed with Volocity Software (Improvision). Scale bar 10 µm. D. Poor UCP4 immunoreactivity (green) was detected in astrocytes (arrows) stained with an antibody against GFAP (red). Blue signal indicates nuclear DNA labeled with DAPI. Scale bar 20 µm. E. Representative CLSM images from rat primary hippocampal neurons demonstrating the co-localization of UCP4 (anti-UCP4 AB, green) with mitochondria (JC1, red). Scale bar 20 µm. side). In contrast, each of these recombinant proteins was detected by antibodies specific for each protein (Fig. 1C, right side) .
Using anti-UCP4-1 (referred to as anti-UCP4 in the text below) as primary AB and Alexa-568-conjugated secondary AB we demonstrated the presence of UCP4 in rat hippocampal (Fig. 1D ) and mouse cortical (data not shown) primary neuronal cultures. To investigate the subcellular localization of UCP4 we (i) double-stained neurons with MitoTracker (Fig. 1D, green) and anti-UCP4 AB (Fig. 1D, red) and (ii) evaluated UCP4 in isolated brain mitochondria (Fig. 2B) by Western blotting. In both cases UCP4 was detected in mitochondria.
Assessment of the tissue-specific expression of mUCP4
Positively evaluated AB against mUCP4 was then used to study the tissue distribution of mUCP4. We analyzed the presence of mUCP4 in different organs, previously described at mRNA level, using Western blotting and IHC. Western blot analysis demonstrated the presence of the protein in whole brain extract (Fig. 2A, lane 1) and no protein bands corresponding to UCP4 in lysates from spleen, lung, thymus, heart, muscles, white adipose tissue, testis, adrenal gland ( Fig. 2A,  lanes 2-9) , large intestine, stomach and small intestine (data not shown) and in mitochondria from liver or kidney (Fig. 2B ). Immunohistochemical data supported these results. Fig. 2C shows liver double-stained for the mitochondrial marker VDAC (visualized by Alexa-568, red) and UCP4 (visualized by Alexa-488, green), revealing the absence of UCP4 in mitochondria of this tissue. Because UCP4-mRNA has been observed in kidney [27] , we performed doubleimmunofluorescence staining of kidney from C57BL/6 mouse with anti-UCP4 and anti-VDAC ABs. Anti-VDAC AB was used as a mitochondrial marker. Our results showed that mitochondria in kidney exhibited strong VDAC-dependent (visualized by Alexa-568, red), but not UCP4-dependent signal (Fig. 2D) .
To test for the presence of UCP4 in the peripheral nervous system (PNS), we carried out the immunological staining of ganglia of different organs including uterus, large intestine and stomach. Confocal laser scanning microscopy revealed that cell bodies of MAP2-positive neurons exhibited only weak immunoreactivity for UCP4. Fig. 2E shows ganglion cells of intramuscular plexus of stomach after staining with anti-MAP2 AB (visualized with Alexa-568, red) and anti-UCP4 AB (visualized with Alexa-488, green).
Expression of UCP4 in different regions of the central nervous system (CNS)
UCP4 expression in different CNS regions of adult mice (5 months old) was assessed by immunohistochemistry ( Fig. 3A-E) and Western blot analysis (Fig. 3F-G) and compared with the distribution of UCP4 mRNA described earlier [1, 6] . Our results confirmed the presence of the protein in all examined brain areas (cortex, brain stem, and cerebellum) and spinal cord at different levels. The results of Western blot quantification showed that UCP4 expression is highest in the cortex of adult mouse (Fig. 3G) , followed by the cerebellum and is present at similar levels in the brain stem and spinal cord. The UCP4 protein amount was normalized to the amount of the mitochondrial marker VDAC to relate the UCP4 concentration to the mitochondrial number, which varied between different regions (Fig. S2, Supplementary  material) . Analyzing the regional UCP4 distribution, we hypothesized that the high UCP4 expression in cortex may reflect the high amount of neurons (or neuronal cell bodies) in this region. To prove this idea we stained the brain regions under study with NeuN (specific for neuronal nuclei and perikarya) and NF (specific for neuronal axons and dendrites). Western blots (Fig. 3F) demonstrate that NeuN is predominantly expressed in cortex and cerebellum. In contrast, the highest expression of NF in the adult mice was detected in the spinal cord and brain stem, which exhibited the lowest expression of UCP4 (Fig. 3F, S4 , Supplementary materials). Immunohistochemical staining of spinal cord (Fig. S4,  Supplementary materials) shows that UCP4 is expressed predominantly in grey matter, which is rich in neuronal cell bodies (visualized by NeuN and MAP2) and poorly expressed in white matter, containing neuronal processes (visualized by NF 68). The mitochondria, visualized by anti-VDAC AB, are distributed equally between grey and white matter.
Cellular and subcellular localization of UCP4
UCP4 content in neurons, astrocytes and microglia cells was evaluated at mRNA and protein levels. Fig. 4A and B show that both protein and mRNA are mainly present in neurons. No UCP4 was detected in microglia cells. To compare the protein expression in neurons and astrocytes, we co-localized anti-UCP4 AB with neuron (MAP2)-or astrocyte (GFAP)-specific markers in double-labeling experiments. Representative confocal images show high expression of UCP4 (Fig. 4C, green) in neurons (Fig. 4C, blue) and much lower immunoreactivity in astrocytes (Fig. 4D, red) confirming the findings of other groups at mRNA and protein levels [6] .
Immunohistochemical staining of brain tissue with ABs against UCP4, MAP2, GFAP and VDAC revealed a similar expression pattern between UCP4 and MAP2 and not between UCP4 and GFAP (Fig. 5A) , indirectly supporting our two observations: low expression of UCP4 in astrocytes ( Fig. 4A and B) and predominant protein expression in neuronal cell body mitochondria (S4, Supplementary material). Confocal microscopy of double-stained brain sections from adult C57BL/6 mice with anti-UCP4 AB (visualized by Alexa-488, green) and monoclonal ABs against VDAC, MAP2, GFAP (all visualized by Alexa-568, red, Fig. 5B ) confirmed our findings.
To test our hypothesis that UCP4 is mainly expressed in mitochondria of neuronal cell bodies, we double-immunostained a primary neuronal culture with anti-UCP4 AB and AB against mitochondrial protein VDAC (Fig. 4C) or with anti-UCP4 AB and potential-sensitive dye JC1 (Fig. 4E) . The co-localization of both markers showed the preferential expression of UCP4 in mitochondria of neuronal cell bodies and in single mitochondria of cell processes. To exclude the artifacts resulting from different confocal levels we performed 3D reconstruction of images taken at different z-levels with Volocity Software (Improvision) (Fig. 4C) .
Assessment of age-dependent expression of UCP4 under physiological conditions
The variation in UCP4 expression during development may be connected to its putative role in ROS regulation, proliferation, differentiation or apoptosis. To determine whether UCP4 is developmentally regulated, we examined brain tissues of fetal and adult mice, and neuronal cell cultures at different ages (days in culture).
Western blot analysis of murine neocortex and hippocampus (Fig. 6A) shows the presence of UCP4 protein as early as E14, followed by protein level increase from embryonic to postnatal stages. The presence of protein in the embryonic brain confirmed the observation that UCP4 mRNA is present in both fetal and adult brain tissues [1] . The comparison of protein expression in cortex, cerebellum, brain stem and spinal cord of mice of different ages demonstrates that amount of UCP4 increases until the adulthood (1, 10, and 30 days) (Fig. S3, A, Supplementary material) , obviously mirroring the rise in mitochondria number shown by VDAC staining (Fig. S3, B , Supplementary material). Toward 5 months old age it remains constant, although the number of mitochondria is still slightly increasing. The direct comparison of UCP4 expression to VDAC expression (Fig. 6B) shows that UCP4 is down-regulated after birth in all mouse CNS regions except the cortex, where the protein levels were nearly constant.
The increase of the absolute amount of UCP is visualized in mouse neuronal cultures immunostained with anti-UCP4 AB. Fig. 6C compares 1, 7 and 21 day-old neurons. Morphologically, young cells of 1 day were smaller, without long processes and with UCP4 predominantly localized in the perinuclear area, obviously reflecting the localization of mitochondria.
Discussion
Using the newly designed and positively evaluated anti-UCP4 AB we demonstrated for the first time that UCP4 is expressed at protein level in different regions of brain and in spinal cord. This is in agreement with the distribution of UCP4 mRNA described by several research groups [1, 6, 7] , but does not support the results of other groups, which showed the expression of mammalian UCP4 mRNA in kidney and omental adipose tissue [34, 35] . Interestingly, high expression levels of atypical UCP4 mRNA were observed in the liver and kidney of Xenopus laevis [36] . The authors proposed that during phylogenesis UCP4 disappears from the periphery and can be found only in brain. This is in contrast to the distribution of UCP2 and UCP5, which are also found in other organs (see Introduction).
The description of UCP4 mRNA distribution among different brain regions in the literature is contradictory. Mao et al. showed the lowest UCP4 mRNA levels in spinal cord, medulla, corpus callosum and substantia nigra [1] . Using immunoblot analysis Liu et al. demonstrated that UCP4 protein amount varies among brain regions. The cortex and hypothalamus appeared to have a larger amount of the protein, however no statistical analysis was performed [6] . Our comparison of different CNS regions in adult mice revealed the highest UCP4 level in cortex, followed by the cerebellum, brain stem and spinal cord (Fig. 3G) . In contrast, the highest levels of UCP2 transcripts have been reported in the spinal cord and medulla [1] , whereas UCP5 transcripts have not been found in spinal cord at all [7] . Using the most specific commercially available anti-UCP2 antibody to date (Santa Cruz Biotechnology Inc, USA) we could not reveal the presence of UCP2 in brain or spinal cord at protein level (data not shown), supporting the data reported by Pecqueur et al. [26] . The regional distribution of UCP4 in brain of adult mice with preference to the cortex (Fig. 3F, G ) is in accordance with its preferential expression in neurons, demonstrated in this work in both brain sections and primary neurons co-cultured with astrocytes. Much lower levels of UCP4 found in astrocytes (Fig. 4A-B, D) and no UCP4 in microglia (Fig. 4A-B ) at protein and mRNA levels are in accordance with the study of Liu et al. [6] and can be indicative for a specific neuronal protein function.
The amount of UCP4 continuously increases until birth, remains almost constant in adult mice if compared to β-actin, (Fig. 6A, Fig. S3 A, Supplementary material) or decreases if compared to the mitochondrial number (UCP4/VDAC, Fig. 6B ). Such a pattern seems to contradict the hypothesized thermogenic function of UCP4 in at least two ways. Firstly, compared with UCP1, which has been confirmed as generating heat in BAT, the expression of UCP4 occurs much earlier than that of UCP1 in BAT of mice, where it appears directly before birth [37] . Secondly, UCP4 content in adult mice decays, which is not compatible with the constant demand for thermoregulation.
Another proposed function for "novel" UCPs is their putative participation in the regulation of ROS. The evaluation of this hypothesis is difficult based on only morphological data. Our data showed a gradual increase of UCP4 in the late gestation period, which may support its proposed regulatory function and reflect the organism's ongoing preparation for birth. However, antioxidant enzymes in the brain have been shown to increase steeply prior to birth [38] [39] [40] , probably due to a sudden increase of oxygen to the organism [38] . Such expression behavior was not seen in our experiments.
ROS in small concentrations are known to be chemical mediators that act on signaling pathways to modulate, among others, growth and differentiation [41] . Our present study reveals that UCP4 appears in brain at E14 (embryonic day 14, Fig. 6A ). This coincides with the initiation of the neurogenesis, which occurs in rodent brain around E12-E14 [42] [43] [44] . On the other hand, we demonstrated that the amount of UCP4 in mitochondria (UCP4/VDAC ratio) decreased after birth in all regions apart from the cortex (Fig. 6B) . Together with the preferential UCP4 expression in neurons this fact may indicate that UCP4 has a specific function in development, e.g. neuronal cell differentiation. Interestingly, when ectopically expressed in preadipocytes, UCP4 promotes their proliferation and inhibits their differentiation in adipocytes [35] .
Summarizing, we have demonstrated that the newly designed affinity purified anti-UCP4 AB to the peptide sequence localized on the N-terminus is specific for UCP4, does not cross-react with other available uncoupling proteins and is restricted to mitochondria. By comparison of the UCP4 distribution with the distribution described for UCP2 and UCP5 in the literature, several significant differences could be established. The highest level of UCP4 in adult mice was found in cortex. The intracellular distribution and developmental expression pattern under physiological conditions do not support the thermoregulatory function of UCP4. Further research is required to evaluate the participation of UCP4 in ROS regulation and neuronal development, to delineate the UCP4 expression under pathological conditions and to reveal the transport modalities of UCP4.
